News J&J adds first new indication for Caplyta since takeover Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.
News Boehringer, Click DTx for schizophrenia clears pivotal trial Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.
Patients Purposeful prescribing in bipolar I disorder care Purposeful prescribing is the idea of making thoughtful, patient-centred decisions about medication.
News UK specialists call for more testing on psychedelics UK psychiatrists have called for a relaxation of restrictive rules on testing psychedelics, which are holding back research and clinical use.
News Rumour partly confirmed as AbbVie acquires Gilgamesh drug Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.
News Welsh biotech Draig emerges with $140m in financing Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.
News MFN model for Medicaid revealed by CMS The Trump administration has released details of a most-favoured nation (MFN) drug pricing programme for medicines provided by Medicaid.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.